First-in-class ADCs and bispecific antibodies for hard-to-treat cancers, guided by patient-derived biology and AI.
New York, NY
Joined January 2021
- Tweets261
- Following495
- Followers492
- Likes397
September is #BloodCancerAwarenessMonth
Worldwide, over 1.3 million people are diagnosed with a blood cancer every year. Survival in several blood cancers has more than doubled in recent decades — and yet roughly 700,000 patients still die of these diseases annually.
At OncoPrecision, much of our focus is on advancing innovative treatments for the blood cancer patients for whom standard therapy falls short.
We're proud to see our Co-Founder & Head of Operations, Dr. Candelaria Llorens, featured in a @forbesargentina article highlighting eight Argentine scientist-founders and their pioneering work across fields from cancer therapeutics to climate-resistant crops.
🔗: forbesargentina.com/innovaci…
OncoPrecision is heading to #BIO2026 🌴
Our CEO, @TarekAliZaki, and Fractional CMO, Dr. Han Myint, will be attending the BIO International Convention, June 22–25 in San Diego, CA and are available for partnering meetings.
We're open to explore strategic collaborations across our platform and pipeline that advance our mission.
If you'd like to connect, please reach out 📩
We're excited to share that our new website is live 🌅
Our mission is to develop first-in-class antibody-drug conjugates (ADCs) and bispecific antibodies for cancers where patients still have too few options. Our lead program, ONC001, is a CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages at the root of disease.
Visit us at oncoprecision.bio/ to learn more about our science, our team, and our commitment to patients.
OncoPrecision retweeted
Great to host an inspiring conversation with 🇦🇷 founders building in the U.S.!
Thanks @nachomarchionna, @JuanMBarrero, @MatiasRecchia, @TarekAliZaki & all participants for a dynamic exchange on innovation, startups & global growth.
Argentina connecting talent with opportunity.
📢 Poster Presentation at #AACR26
We are pleased to share that data from ONC001, our first-in-class CD64-targeting antibody-drug conjugate (ADC), will be presented at the AACR Annual Meeting.
🔗 linkedin.com/feed/update/urn…
We’re pleased to share that our Co-Founder & CSO, @Gastonsoria, will be speaking at the 4th Annual ADC Linker & Conjugation Summit this July.
linkedin.com/posts/oncopreci…
📢 Oral Presentation at #ASH25
We are pleased to share that data from ONC001, our first-in-class CD64-targeting ADC, will be presented by our Co-Founder & Chief Scientific Officer, Dr. Gastón Soria, at the 67th ASH Annual Meeting and Exposition.
🔗: prnewswire.com/news-releases…
October is hashtag#BreastCancerAwarenessMonth — a reminder of courage, resilience, and the power of science to bring hope 🎀🎀
This month, we’re shining a light on the importance of regular screening, early detection, and continued innovation in the search for new treatments.
Blood cancers affect over 1.2 million people worldwide each year. This #BloodCancerAwarenessMonth, we are reminded of our commitment to raise awareness, support those impacted, and continue to push the boundaries of science so that every patient has a better tomorrow 🩸🧡
OncoPrecision is heading to #BIO2025!
We look forward to engaging with partners, industry leaders, and innovators to exchange ideas, explore strategic collaborations, and advance patient-centric drug discovery efforts for novel cancer therapies.
On this hashtag#WorldCancerDay we stand united with patients, their families, and all lives that are touched by cancer, as we strive to advance much-needed transformative therapies 🧡
Our CEO, @TarekAliZaki, will be participating in a panel discussion on Leveraging the Global Landscape: New Pathways and Geographies in Drug Development on January 15th hosted by @SOSV's @indbio and LOTTE Ventures U.S.
lu.ma/ew7dbw2n
Some of this year’s #ASH24 highlights pictured: catching up with our dear Advisors (Dr. @DrGwenNichols, Chief Medical Officer of @LLSusa at their stand and Dr. Jorge Solimano, VP and Head of Hematology of CEMIC over lunch), our annual picture with the ASH sign, and a bit of fun.
OncoPrecision retweeted
This weekend, we’re presenting preclinical data from our #CMML & #AML programs at #ASH24 in San Diego. We’re proud to collaborate with experts from @MayoClinic, @MDAndersonNews, @DiscLS, and @OncoPrecision1. Read about our accepted abstracts: bit.ly/3OC7tUS
We’re thrilled to welcome Dr. Stefan Oschmann to our Advisory Board.
Dr. Oschmann served as Chairman & CEO of Merck KGaA from 2016 to 2021, successfully leading the company through a period of transformation and growth.
linkedin.com/feed/update/urn…
